“Another pandemic is upon us, and policymakers are once again proving slow to respond, to the detriment of global health,” writes Henry B. Skinner, CEO of the AMR Action Fund, in Harvard Public Health.
It’s antimicrobial resistance–or AMR–which “took 1.27 million lives in 2019, more than HIV/AIDS or malaria,” and the number is expected to grow if we don’t develop new antibiotics and antimicrobials.
He explains the scale of the problem and how pharmaceutical companies and policymakers are working to address AMR and the antibiotic pipeline – read the whole thing in Harvard Public Health.
About the AMR Action Fund
The AMR Action Fund is a broad alliance of pharmaceutical industry and non-industry stakeholders with the aim to develop 2-4 new antibiotics by 2030. The AMR Action Fund “expects to invest more than US$1 billion in smaller biotech companies and provide industry expertise to support the clinical development of novel antibiotics.” Learn more about the AMR Action Fund.
More AMR Reading:
- Panel decries lack of attention for antimicrobial resistance
- AMR Action Fund’s first investments support innovation to fight superbugs
- In reaction to AMR threat, scientists call for new market approaches to antibiotic development